ArticleBMJ open2024

Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.

Jinfeng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.